Company Overview and News
You might not be aware of it, but big pharma stocks have gone through a difficult period for many years. A lot of the big drugs at the big pharma stocks went off patent, and the revenue for some of the big pharma stocks has fallen off as a result.
A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It wasn’t great news for Pfizer stock, but it wasn’t tragic either.
Pfizer Inc. (PFE - Free Report) announced that the FDA has granted Breakthrough Therapy designation to its rare disease candidate, tafamidis. The candidate is being developed for the treatment of transthyretin cardiomyopathy (TTR-CM).
With three product candidates in the pipeline, at a very early stage, Scholar Rock will need a long time to see the FDA approving them. That said, the company has many patents, a licence with Janssen Biotech, and a fantastic team of professionals. While the risk may be too high for the individual investors, the institutional traders must have a look at it.
At the same time, the risk is also very high. Shareholders can lose almost all their money.
Which top stocks are Wall Street analysts the most bullish on? Stocks with no “hold” or “sell” ratings and a pure “Strong Buy” analyst consensus. These are the stocks that make the most compelling investing opportunities and are definitely worth keeping a close eye on.
Pfizer Inc. (PFE - Free Report) announced that a phase III study evaluating its epilepsy drugLyrica (pregabalin) in pediatric patients met the primary endpoint. The study was evaluating the use of Lyrica Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age, an indication for which Lyrica is not yet approved.
(Reuters) - Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer’s drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease.
The Dow snapped a record streak of wins to traverse a turbulent week. Trade-war related concerns continued to weigh on investors with President Trump expressing doubts over the success of upcoming negotiations with China. Additionally, the spike in 10-year Treasury yield also spooked markets, sparking off fresh inflationary concerns. Such fears were also stoked by encouraging retail sales numbers.
All three drugmakers included in the Dow Jones industrial index were on a list of drug companies published Thursday by the U.S. Food and Drug Administration (FDA) alleged to have withheld samples of brand-name drugs from companies wanting to develop generic versions of the drugs. Merck & Co. Inc. (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) each dropped more than 1% while Pfizer Inc. (NYSE: PFE) posted a gain of less than 0.
Biotech and drug company stocks involve a different type of investing. The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA).
Iterum Therapeutics intends to raise $80 million from the sale of its common stock in a U.S. IPO.
Pfizer Inc. (PFE - Free Report) announced that the FDA has granted approval to Retacrit, a biosimilar version of two blockbuster drugs – Amgen Inc.’s (AMGN - Free Report) Epogen and Johnson & Johnson’s (JNJ - Free Report) Procrit. Pfizer already markets the biosimilar in Europe
(Reuters) - Pfizer Inc’s Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands.
Pfizer Inc's biosimilar of anemia treatments from Amgen Inc and Johnson & Johnson was approved by U.S. health regulators on Tuesday setting it up to compete against the established brands.
22h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
22h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...